Encouraging clinical data reported from Phase 1/2 trial of sepofarsen for LCA10
Initial clinical data from Phase 1/2 trial of QR-421a for Usher syndrome type 2 on track for Q1 2020
QR-1123 Investigational New Drug application active for autosomal dominant re
… QR-421a, An Antisense Oligonucleotide for the Treatment of Retinitis Pigmentosa Due To USH2A Exon 13 Mutations … amaurosis 10, Usher syndrome type 2 and autosomal dominant retinitis pigmentosa. Based on our unique proprietary RNA …
… including mutations causing LCA10, Usher syndrome, and retinitis pigmentosa for which ProQR is developing medicines. … amaurosis 10, Usher syndrome and autosomal dominant retinitis pigmentosa. Based on the unique proprietary RNA … spectrum of retinal degenerative diseases including: retinitis pigmentosa, age-related macular degeneration, Usher …
… type of antisense oligonucleotide treatment (QR-421a) for retinitis pigmentosa (RP) due to exon 13 USH2A mutations … an antisense oligonucleotide, for the treatment of retinitis pigmentosa due to USH2A exon 13 mutations … of vision loss in Usher syndrome type 2 and non-syndromic retinitis pigmentosa (RP) due to mutations in exon 13 of the …
… for QR-421a for Usher syndrome type 2 and non-syndromic retinitis pigmentosa (RP) due to mutations in exon 13 of the … mutations in exon 13. QR-1123 for autosomal dominant retinitis pigmentosa (adRP) In October, ProQR in-licensed … of vision loss in Usher syndrome type 2 and non-syndromic retinitis pigmentosa (RP) due to mutations in exon 13 of the …
… associated with Usher syndrome type 2 and non-syndromic retinitis pigmentosa (RP) due to mutations in exon 13 of the … of vision loss in Usher syndrome type 2 and non-syndromic retinitis pigmentosa (RP) due to mutations in exon 13 of the …
… associated with Usher syndrome type 2 and non-syndromic retinitis pigmentosa (RP) due to mutations in exon 13 of the … of vision loss in Usher syndrome type 2 and non-syndromic retinitis pigmentosa (RP) due to mutations in exon 13 of the …
… in patients with Usher syndrome type 2 or non-syndromic retinitis pigmentosa (RP). Interim data from the study are … of vision loss in Usher syndrome type 2 and non-syndromic retinitis pigmentosa (RP) due to mutations in exon 13 of the …
… Drug Designation by the FDA and EMA for the treatment of retinitis pigmentosa, including Usher syndrome, the subtype … and European Medicines Agency (EMA) for the treatment of retinitis pigmentosa, including Usher syndrome, the subtype …
… Deep-Intronic c.7595-2144A>G Mutation Associated with Retinitis Pigmentosa in Usher Syndrome Type 2 QRX-421, an RNA … Targeting Mutations in Exon 13 of USH2A, Associated with Retinitis Pigmentosa in Usher Syndrome Type 2, is Effective …